Contents of this article
The 6th edition of the Hanson Wade Bacteriophage Therapy Summit will be held in Boston, USA from Tuesday 27th February till Thursday 29th February 2024.
What is the 6th Bacteriophage Therapy Summit and Why attend?
This is your unique opportunity to be a part of the dialogue, and meet phage leaders, large pharma, and venture capitalists from the likes of Merck, Pfizer, SNIPR Biome, Locus Biosciences, and AMR Action Fund. 3 days of unmissable content, and insights to accelerate your bacteriophage research into clinical, meaningful and commercially viable therapies, going beyond AMR.
As the only global platform for industry-dominated phage drug developers, the 6th Bacteriophage Therapy Summit will return to Boston in 2024 to integrate 90+ phage experts to:
- Strategize how to design an ideal clinical trial for a successful IND filing and regulatory approval
- Discover how to accelerate phage discovery for better patient outcomes through AI applications
- Leverage next-generation sequencing to foster technological innovation and engineer phage therapy
- Optimize process development and analytics to obtain higher yields and improve manufacturability
- Transcend beyond treatment of AMR to address critical challenges in Precision Medicine and Oncology
Who will be at the 6th Bacteriophage Therapy Summit?
Key global leaders from both the US and Europe will be attending.
The summit will bring together individuals in positions and occupations of; Chiefs, CSOs, Directors, Heads, Managers, Professors and Scientists. Those who work in a diversity of fields such as; drug development, non-profit organizations, academia, service providers, and consumer brands.
Agenda for the 6th Bacteriophage Therapy Summit 2024
Tuesday 27th February 2024
Pre-conference Workshop
Mayukh Das Chief Operations Officer at Phiogen – Enhancing Clinical Outcomes & Success Rates: Optimizing Bacteriophage Drug Development Platforms
Carrie-Lynn Furr CEO at BDDC – Tailored Fundraising & Business Model for Bacteriophage Therapy Development & Commercial Viability
Wednesday 28th February 2024
Urania Rappo Senior Director in Clinical Development at Biomx – Shedding Light on Success of Bacteriophage Clinical Trials on Humans
Paul Kim Chief Development Officer at Locus Biosciences – Advancing Towards Clarity on Combating Urinary Tract Infections with PhageBased Clinical Study
Sofia Corte-Real Chief Scientific Officer at TechnoPhage – Management of Diabetic Foot Infections Using Phage Products: Unveiling TP-102 Phase IIb Study
Mina Pastagia Chief Medical Officer at Armata Pharmaceuticals – Exhibiting Clinical Trials Overview of Bacteriophage Administration for Difficult-To-Treat Infections
Johan Wikstrom CEO at Tolka AI Therapeutics – Lessons Learned from Google: Applying AI in Practice for Development & Production of Bacteriophage
Jakob Krause Haaber Vice President of CRISPR & Delivery Technologies at SNIPR Biome – Gaining Insights into Clinical Testing of Engineered Phage Cocktail Targeting E. coli
Keiko Salazar Assistant Director at Baylor College of Medicine – Discovering, Purifying & Selecting the Appropriate Cocktail Phage for Personalized Medicine
James Cass Director of Molecular & Viral Safety at Merck – Translating Our Process Development into Good Manufacturing Practice with Cost of Goods in Mind
Danish Malik Professor in Industrial Biotechnology at University of Loughborough – Process Monitoring & Controlling Critical Process Parameters to Obtain Higher Phage Yields in Upstream & Downstream Manufacturing
Danish Malik Professor in Industrial Biotechnology at University of Loughborough, James Cass Director of Molecular & Viral Safety at Merck, and Paul Kim Chief Development Officer at Locus Biosciences – What’s the Future of Bacteriophage from a Manufacturing Suitability Perspective?
Thursday 29th February 2024
Matjaz Peterka CEO at COBIK – Enhancing Translatability Ahead of Clinical Trials for Effective Treatment of Prosthetic Joint Infections
Amanda Burkardt CEO at Phiogen – Disrupting Modern Day Medicine: Re-Inventing Strategies Around Phage Drug Development
Pablo Cifuentes Chief Technology Officer at PhageLab – Examining Phage Development Process in the Agricultural Industry: How Can We Translate This Over to Pharmaceuticals?
Jason Clark Chief Scientific Officer at NexaBiome – Traveling Broadens the Mind: Exploring the Journey from Agritech to Human Health
Jaroslaw Dastych CEO at Proteon Pharmaceuticals – Breaking the Ice: Pioneering Bacteriophage Product Acceptance in the European Regulatory Landscape
Jaroslaw Dastych CEO at Proteon Pharmaceuticals, Jason Clark Chief Scientific Officer at NexaBiome, and Pablo Cifuentes Chief Technology Officer at PhageLab – What Can be Taken from the Agricultural Bacteriophage Industry & Applied to Human Use?
Dylan Lawrence Senior Scientist at Pfizer – Characterizing the Role of Microbiome on Human Health to Understand How Bacteriophage Contributes to Preventative Medicine
Adi Elkeles CEO at Trobix Bio – Next Therapy for Precision Oncology: Utilizing Bacteriophage for Targeting Microbiome & Applying Synthetic Biology
Sergei Petukhov Managing Director at AMR Action Fund – Moderating Roundtable Discussion: Evaluating the Future of Natural, Engineered, Hybrid & Synthetic Phage
View past events by Hanson Wade
